50
Participants
Start Date
February 23, 2016
Primary Completion Date
December 2, 2020
Study Completion Date
July 15, 2027
Olaparib
Olaparib starts concomitantly with the first dose of Tremelimumab
Tremelimumab
3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
University of Virginia Cancer Center, Charlottesville
Moffitt Cancer Center, Tampa
The Ohio State University, Columbus
Southwest Gynecologic Oncology Associates, Albuquerque
University of New Mexico Comprehensive Cancer Center, Albuquerque
New Mexico Cancer Research Alliance
OTHER